AU2002236753B2 - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents
An improved process for preparing pure ondansetron hydrochloride dihydrate Download PDFInfo
- Publication number
- AU2002236753B2 AU2002236753B2 AU2002236753A AU2002236753A AU2002236753B2 AU 2002236753 B2 AU2002236753 B2 AU 2002236753B2 AU 2002236753 A AU2002236753 A AU 2002236753A AU 2002236753 A AU2002236753 A AU 2002236753A AU 2002236753 B2 AU2002236753 B2 AU 2002236753B2
- Authority
- AU
- Australia
- Prior art keywords
- hydrochloride dihydrate
- ondansetron
- ondansetron hydrochloride
- weight
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26105201P | 2001-01-11 | 2001-01-11 | |
US60/261,052 | 2001-01-11 | ||
PCT/US2002/000853 WO2002055492A2 (fr) | 2001-01-11 | 2002-01-11 | Procede ameliore permettant la preparation de chlorhydrate dihydrate d'ondansetron |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002236753A1 AU2002236753A1 (en) | 2003-02-06 |
AU2002236753B2 true AU2002236753B2 (en) | 2007-06-28 |
Family
ID=22991757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002236753A Expired - Fee Related AU2002236753B2 (en) | 2001-01-11 | 2002-01-11 | An improved process for preparing pure ondansetron hydrochloride dihydrate |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1355881A4 (fr) |
JP (1) | JP2004526692A (fr) |
KR (3) | KR20060113792A (fr) |
CN (2) | CN101045704A (fr) |
AU (1) | AU2002236753B2 (fr) |
CA (1) | CA2433720A1 (fr) |
CZ (1) | CZ20032090A3 (fr) |
DE (1) | DE02703115T1 (fr) |
ES (1) | ES2219201T1 (fr) |
HR (1) | HRP20030631A2 (fr) |
HU (1) | HUP0400767A2 (fr) |
IL (1) | IL156835A0 (fr) |
IS (1) | IS6869A (fr) |
MX (1) | MXPA03006215A (fr) |
NO (1) | NO20033147L (fr) |
PL (1) | PL368837A1 (fr) |
SK (1) | SK9892003A3 (fr) |
TR (1) | TR200401460T3 (fr) |
WO (1) | WO2002055492A2 (fr) |
YU (1) | YU56103A (fr) |
ZA (1) | ZA200305338B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1499623E (pt) | 2002-04-29 | 2007-08-10 | Teva Gyogyszergyar Zartkoeruee | ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona'' |
HU225885B1 (en) * | 2002-10-17 | 2007-11-28 | Richter Gedeon Nyrt | Process for producing ondansetron hydrochlorid dihydrate of high purity |
FI6164U1 (fi) * | 2003-01-09 | 2004-03-15 | Synthon Bv | Ondansetronmuotoja |
GB2398071B (en) * | 2003-01-24 | 2006-06-07 | Synthon Bv | Process for making ondansetron and intermediate thereof |
US7696356B2 (en) | 2004-08-17 | 2010-04-13 | Taro Pharmaceutical Industries Limited | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom |
EP1828141A4 (fr) * | 2004-10-26 | 2009-04-01 | Ipca Lab Ltd | Procede monotope de preparation de l'agent antiemetique 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazol-4-one |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
US4835173A (en) * | 1986-12-17 | 1989-05-30 | Glaxo Group Limited | Method of medical treatment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE01991193T1 (de) * | 2000-10-30 | 2004-07-08 | Teva Pharmaceutical Industries Ltd. | Neue kristall- und solvatformen von ondansetronhydrochlorid und verfahren zu deren herstellung |
-
2002
- 2002-01-11 SK SK989-2003A patent/SK9892003A3/sk not_active Application Discontinuation
- 2002-01-11 JP JP2002556165A patent/JP2004526692A/ja active Pending
- 2002-01-11 HU HU0400767A patent/HUP0400767A2/hu unknown
- 2002-01-11 CN CNA2006101667179A patent/CN101045704A/zh active Pending
- 2002-01-11 EP EP02703115A patent/EP1355881A4/fr not_active Withdrawn
- 2002-01-11 CN CNA028062019A patent/CN1496350A/zh active Pending
- 2002-01-11 PL PL02368837A patent/PL368837A1/xx not_active Application Discontinuation
- 2002-01-11 IL IL15683502A patent/IL156835A0/xx unknown
- 2002-01-11 YU YU56103A patent/YU56103A/sh unknown
- 2002-01-11 DE DE02703115T patent/DE02703115T1/de active Pending
- 2002-01-11 ES ES02703115T patent/ES2219201T1/es active Pending
- 2002-01-11 CZ CZ20032090A patent/CZ20032090A3/cs unknown
- 2002-01-11 WO PCT/US2002/000853 patent/WO2002055492A2/fr active Application Filing
- 2002-01-11 TR TR2004/01460T patent/TR200401460T3/xx unknown
- 2002-01-11 KR KR1020067020069A patent/KR20060113792A/ko not_active Application Discontinuation
- 2002-01-11 KR KR10-2003-7009221A patent/KR20030068583A/ko active IP Right Grant
- 2002-01-11 CA CA002433720A patent/CA2433720A1/fr not_active Abandoned
- 2002-01-11 ZA ZA200305338A patent/ZA200305338B/xx unknown
- 2002-01-11 KR KR1020077010146A patent/KR20070054749A/ko not_active Application Discontinuation
- 2002-01-11 AU AU2002236753A patent/AU2002236753B2/en not_active Expired - Fee Related
- 2002-01-11 MX MXPA03006215A patent/MXPA03006215A/es unknown
-
2003
- 2003-07-08 IS IS6869A patent/IS6869A/is unknown
- 2003-07-09 NO NO20033147A patent/NO20033147L/no not_active Application Discontinuation
- 2003-08-06 HR HR20030631A patent/HRP20030631A2/hr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
US4835173A (en) * | 1986-12-17 | 1989-05-30 | Glaxo Group Limited | Method of medical treatment |
Non-Patent Citations (1)
Title |
---|
Zhongguo yiyao Gongye Zazhi, Chinese Journal of Pharmaceuticals, 1993, 24 (6): 241-242 * |
Also Published As
Publication number | Publication date |
---|---|
MXPA03006215A (es) | 2005-02-17 |
JP2004526692A (ja) | 2004-09-02 |
KR20030068583A (ko) | 2003-08-21 |
CA2433720A1 (fr) | 2002-07-18 |
ZA200305338B (en) | 2004-07-12 |
EP1355881A2 (fr) | 2003-10-29 |
CN1496350A (zh) | 2004-05-12 |
ES2219201T1 (es) | 2004-12-01 |
IS6869A (is) | 2003-07-08 |
YU56103A (sh) | 2006-05-25 |
DE02703115T1 (de) | 2004-10-21 |
PL368837A1 (en) | 2005-04-04 |
EP1355881A4 (fr) | 2004-03-31 |
WO2002055492A2 (fr) | 2002-07-18 |
HRP20030631A2 (en) | 2005-06-30 |
KR20070054749A (ko) | 2007-05-29 |
IL156835A0 (en) | 2004-02-08 |
WO2002055492A3 (fr) | 2003-02-13 |
CZ20032090A3 (cs) | 2004-08-18 |
KR20060113792A (ko) | 2006-11-02 |
TR200401460T3 (fr) | 2004-08-23 |
NO20033147D0 (no) | 2003-07-09 |
NO20033147L (no) | 2003-09-02 |
CN101045704A (zh) | 2007-10-03 |
SK9892003A3 (en) | 2004-05-04 |
HUP0400767A2 (hu) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021202576B2 (en) | Fenfluramine compositions and methods of preparing the same | |
US8501935B2 (en) | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto | |
JP7253624B2 (ja) | 4-メトキシピロール誘導体の製造方法 | |
CN105061414B (zh) | 一锅法制备Brexpiprazole | |
WO2006001846A1 (fr) | Methode de production de 7-(4-bromobutoxy)-3,4-dihydrocarbostyrile | |
EP2948432B1 (fr) | Procédé de préparation d'ivabradine | |
EP3015453B1 (fr) | Procédé de préparation de clomiphène | |
AU2002236753B2 (en) | An improved process for preparing pure ondansetron hydrochloride dihydrate | |
JP2008511684A (ja) | アナストロゾール中間体についての精製方法 | |
AU2002236753A1 (en) | An improved process for preparing pure ondansetron hydrochloride dihydrate | |
US20100063299A1 (en) | Process for Preparing Irbesartan | |
TWI291956B (en) | Improved process | |
US5877351A (en) | Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts | |
US20020115707A1 (en) | Process for preparing pure ondansetron hydrochloride dihydrate | |
EP3015454A1 (fr) | Forme solide stable de trans-clomiphène citrate | |
EP1412340A2 (fr) | Procede servant a preparer hydrobromure de citalopram | |
EP2072510A1 (fr) | Forme cristalline d'azélastine | |
KR100342919B1 (ko) | 트랜스체 염산 트라마돌의 분리 제조방법 | |
EP3759081A1 (fr) | Procédé de préparation amélioré de maléate de propiomazine | |
CN110885315A (zh) | 左西孟旦药重要中间体的制备方法 | |
WO2002048120A1 (fr) | Nouveaux cristaux de derives d'oxazepine et procede de production de ces derniers | |
WO2008095964A1 (fr) | Forme cristalline de la base de moxifloxacine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |